Cargando…

Enhancing the anti-angiogenic action of histone deacetylase inhibitors

BACKGROUND: Histone deacetylase inhibitors (HDACIs) have many effects on cancer cells, such as growth inhibition, induction of cell death, differentiation, and anti-angiogenesis, all with a wide therapeutic index. However, clinical trials demonstrate that HDACIs are more likely to be effective when...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuljaca, Selena, Liu, Tao, Tee, Andrew EL, Haber, Michelle, Norris, Murray D, Dwarte, Tanya, Marshall, Glenn M
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2173905/ https://www.ncbi.nlm.nih.gov/pubmed/17958916 http://dx.doi.org/10.1186/1476-4598-6-68

Ejemplares similares

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1
por: Shahbazi, Jeyran, et al.
Publicado: (2014)

Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies
por: Imai, Yoichi, et al.
Publicado: (2016)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Prominent action of butyrate over β-hydroxybutyrate as histone deacetylase inhibitor, transcriptional modulator and anti-inflammatory molecule
por: Chriett, Sabrina, et al.
Publicado: (2019)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
por: Tan, Jiahuai, et al.
Publicado: (2010)

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
por: Dickinson, Michael, et al.
Publicado: (2010)

Targeting histone deacetylases for the treatment of disease
por: Lawless, M W, et al.
Publicado: (2009)

Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer
por: Alzoubi, Samer, et al.
Publicado: (2016)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
por: Xiao, Lin, et al.
Publicado: (2022)

Antitumor Action of a Novel Histone Deacetylase Inhibitor, YF479, in Breast Cancer()
por: Zhang, Tao, et al.
Publicado: (2014)

Hypothalamic leptin action is mediated by histone deacetylase 5
por: Kabra, Dhiraj G., et al.
Publicado: (2016)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors
por: MacTavish, Heather, et al.
Publicado: (2010)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Regulation of Immune Responses by Histone Deacetylase Inhibitors
por: Licciardi, Paul V., et al.
Publicado: (2012)

Interpreting clinical assays for histone deacetylase inhibitors
por: Martinet, Nadine, et al.
Publicado: (2011)

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
por: Stintzing, Sebastian, et al.
Publicado: (2011)

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
por: Bishton, Mark J., et al.
Publicado: (2010)

Dual Inhibitors Against Topoisomerases and Histone Deacetylases
por: Seo, Young Ho
Publicado: (2015)

Attenuation of Choroidal Neovascularization by Histone Deacetylase Inhibitor
por: Chan, Nymph, et al.
Publicado: (2015)

Zinc binding groups for histone deacetylase inhibitors
por: Zhang, Lei, et al.
Publicado: (2018)

The effect of histone deacetylase inhibitors on AHSP expression
por: Okhovat, Mohammad Ali, et al.
Publicado: (2018)

Histone Deacetylase Inhibitors and Diabetic Kidney Disease
por: Hadden, Mitchell J., et al.
Publicado: (2018)

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
por: Li, Guo, et al.
Publicado: (2020)

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
por: Verza, Flávia Alves, et al.
Publicado: (2020)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022)

Next-generation of selective histone deacetylase inhibitors
por: Yang, Feifei, et al.
Publicado: (2019)

Histone Deacetylase Inhibitors from Marine Invertebrates
por: Luparello, Claudio, et al.
Publicado: (2020)

Antitheilerial Activity of the Anticancer Histone Deacetylase Inhibitors
por: Barman, Madhumanti, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_blgacjgio05m4098tatm8c3oas